• Recce Pharmaceuticals received AUD $5.3m R&D Tax Incentive rebate from the Australian Taxation Office
• The rebate supports Recce's R&D activities, including ongoing Phase 3 clinical trial in Indonesia
• Recce expects a further AUD $3m rebate, providing additional non-dilutive funding

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has received a cash refund of AUD $5,339,202 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2025. The rebate reflects R&D activities undertaken locally and overseas, and is provided to the company in cash, without caveat. The Australian Government's 43.5% Research & Development Tax Incentive rebate supports Australian innovation, allowing Recce to capture 43.5% of its R&D applicable activities undertaken anywhere in the world. Recce has also lodged a further R&D Tax Incentive submission in respect of additional eligible activities, and expects a further cash refund of approximately AUD $3.0m, which would complete the company's FY25 R&D rebate and provide additional non-dilutive funding. Recce Pharmaceuticals' CEO, James Graham, stated that the substantial rebate will go towards funding the company's R&D programs, both locally and overseas, including its ongoing Phase 3 Clinical Trial in Indonesia, and further domestic clinical programs. The funds received provide further confidence in Recce's objectives and support the continued progression of the company's anti-infective portfolio.

The funds received from the R&D rebate will provide additional non-dilutive funding to support Recce Pharmaceuticals' ongoing R&D programs, including its Phase 3 clinical trial in Indonesia and further domestic clinical programs, as the company continues to progress its anti-infective portfolio.